Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about FDA Approves Janssen Biotech’s STELARA ® (Ustekinumab)
Janssen Biotech, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved STELARA ® (ustekinumab) for the treatment of moderately to severely active Crohn’s disease in adults (18 years or older) who have failed or were intolerant to treatment with immunomodulators or corticosteroids but never failed treatment with a tumor necrosis factor (TNF) blocker, or who failed or were intolerant to treatment with one or more TNF blockers. STELARA ® is the first biologic therapy for Crohn’s disease targeting interleukin (IL)-12 and IL-23 cytokines, which play a key role in inflammatory and immune responses.
- Read more about Gujarat has Evolved into a Major Pharmaceutical Hub in India, Contributing More than 20% to the Sector’s National Turnover
Leading the way in becoming an inspirational model for pharmaceutical sector, Gujarat has evolved into a hub for major pharmaceutical companies. Many investment-friendly initiatives and growth propelling policies in industries such as pharmaceutical & biotechnology, textile, auto, gems & jewellery, IT, maritime & port and engineering are significantly driving growth for the state.
- Read more about Marksans Pharma Ltd announces USFDA approval for Loratadine Liquid Filled Capsules 10 mg (ANDA 206214)
Marksans Pharma Limited announces that USFDA has granted approval for an Abbreviated New Drug Application (ANDA) for Loratadine Liquid Filled Capsules 10 mg.
- Read more about Novartis receives three new FDA approvals for the expanded use of Ilaris
Novartis announced that the US Food and Drug Administration (FDA) has granted three simultaneous approvals for the expanded use of Ilaris® (canakinumab) to treat three rare and distinct types of Periodic Fever Syndromes.
- Read more about FDA Approves Amgen's AMJEVITA™ For Treatment Of Seven Inflammatory Diseases
Amgen announced that the U.S. Food and Drug Administration (FDA) has approved AMJEVITA™ (adalimumab-atto) across all eligible indications of the reference product, Humira® (adalimumab). AMJEVITA is the first adalimumab biosimilar approved by the FDA and has been approved for the treatment of seven inflammatory diseases, including moderate-to-severe rheumatoid arthritis, moderate-to-severe polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, moderate-to-severe chronic plaque psoriasis, adult moderate-to-severe Crohn's disease and moderate-to-severe ulcerative colitis. AMJEVITA is Amgen's first biosimilar to receive regulatory approval.

[adsense:336x280:8701650588]
- Read more about FDA Approve Allergan’s NATRELLE INSPIRA® Cohesive Breast Implants
Allergan plc announced the company has received approval from the U.S. Food and Drug Administration (FDA) to market NATRELLE INSPIRA® Cohesive breast implants, offering women undergoing reconstruction, augmentation or revision surgery a new breast shaping option that combines a high gel fill ratio and Allergan's highly cohesive gel for a customized result. The new NATRELLE INSPIRA® Cohesive line of breast implants is the newest entry into the category of breast implants commonly referred to as "gummy" implants, designed for women who are interested in increased breast fullness.
- Read more about Adamas & Allergan declare U.S. Availability of New Dosage Strengths for NAMZARIC Extended Release
Allergan plc and Adamas Pharmaceuticals, Inc announced that all four dosage strengths of NAMZARIC® (memantine and donepezil hydrochlorides) extended-release capsules that allow patients on donepezil 10 mg to start directly on NAMZARIC are now available by prescription in pharmacies throughout the U.S. NAMZARIC is a once-daily, fixed-dose combination of memantine hydrochloride (a NMDA receptor antagonist) and donepezil hydrochloride (an acetylcholinesterase inhibitor, AChEI) for the treatment of moderate to severe Alzheimer's Disease in patients stabilized on 10 mg of donepezil hydrochloride once daily. NAMZARIC'S new indication and dosage strengths were approved by the U.S. Food and Drug Administration (FDA) in July 2016.
- Read more about Treatments for Dementia and Alzheimer's Disease possible with Chinese medicine
A new study of classical Chinese medical texts identifies references to age-related memory impairment similar to modern-day Alzheimer's disease, and to several plant-based ingredients used centuries ago -- and still in use today -- to treat memory impairment. Experimental studies of five of these traditional Chinese medicines suggest that they have biological activity relevant to Alzheimer's disease, according to an article in The Journal of Alternative and Complementary Medicine, a peer-reviewed publication from Mary Ann Liebert, Inc.
- Read more about The Scripps Research Institute Study Illuminates How Mystery MS Drug Works
A study by scientists at The Scripps Research Institute (TSRI) has helped to de-mystify the molecular workings of the multiple sclerosis (MS) drug Tecfidera®. The drug is the most widely prescribed pill-based therapy for MS, but its biological mechanism remains mysterious.
- Read more about FDA approves Amjevita, a biosimilar to Humira
The U.S. Food and Drug Administration approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases.